Value-based medicine.
Kymes
Steven M
SM
Vollman
David
D
Frick
Kevin D
KD
D020533:Angiogenesis Inhibitors / Q000191:economics*; D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005584:Fovea Centralis; D006304:Health Status; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy / Q000191:economics*; D008390:Markov Chains; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab